Introduction {#sec1-1}
============

Psychodermatological (PD) conditions are not uncommon in clinical practice. They may present as primary psychiatric disorders such as delusions of parasitosis (DP), dermatitis artefacta etc., or as chronic dermatoses such as atopic eczema or psoriasis, patients of which may have depression or anxiety secondary to their skin disease. In a study from Manipal,\[[@ref1]\] 33% of the patients attending a psychodermatology liaison clinic had psychiatric co-morbidity. Since, psychological components contribute to the overall dermatological outcomes, managing them is of importance. It is essential for a clinical dermatologist to have a working knowledge of common psychiatric conditions as well as the use of psychotropic medications. Although DP is infrequently encountered, dysthymia is common in routine practice.\[[@ref2]\] Present article addressesrole of psychopharmacotherapy in PD conditions.

Antipsychotics {#sec1-2}
==============

Antipsychotics are the drugs of choice in delusional disorders such as DP.\[[@ref3]\] They are also useful in body focused repetitive behaviors such as trichotillomania (TTM)\[[@ref4]\] and skin picking disorder.\[[@ref5]\] Owing to their multi-receptor action, they are sometimes used in pruritus\[[@ref6][@ref7]\] and hyperhidrosis.\[[@ref8]\] They are divided into first-generation antipsychotics (FGAs; neuroleptics, conventional, or typical anti psychotics) and second-generation anti psychotics (SGAs; atypical). The increased incidence of extrapyramidal syndromes (EPS) such as akathisia (feeling of restlessness), Parkinsonism (slow movements, slow speech, tremors, and facial stiffness), tardive dyskinesia (irregular jerky movements), and dystonia (spasms and muscle contractions) with FGAs are the main differences between FGAs and SGAs.

All FGAs act by inhibiting the dopamine D2 receptors in the brain and in addition to EPS, hyperprolactinemia is also seen with their use. Of various agents in FGAs, last decades have witnessed the effective and wide usage of pimozide for DP. It is available as 2 mg and 4 mg tablets and may be started at a dose of 0.5 mg/day and up to 6mg daily at 8--12 hourly intervals. Prophylactic anticholinergics (trihexyphenidyl 2 mg tid, benztropine 1--2 mg qid, or diphenhydramine 25--50 mg every 4 to 6 h) can be given to prevent EPS. In a study of 33 patients with DP who were prescribed pimozide,\[[@ref9]\] only 18 took it and on follow-up, five had complete remission, four were less symptomatic, five were unchanged, and four died of unrelated causes. Owing to the high incidence of EPS and cardiac effects such as Q-T interval prolongation with pimozide, it has been superseded by Second Generation A ntipsychotics (SGAs). The drug interactions of pimozide such as serious cardiotoxicity with itraconazole and macrolides, the necessity of frequent monitoring with ECG and serum potassium levels, and the occurrence of neuroleptic malignant syndrome (fever, muscle rigidity, confusion, and dysrhythmias) have precluded its use as a first-line treatment in DP.

Currently, SGAs are the preferred drugs in DP, among which risperidone is considered as the drug of choice.\[[@ref10]\] The other drugs in this class are clozapine, olanzapine, quetiapine, aripiprazole, ziprasidone, and lurasidone. SGAs act by binding to D2 receptors as well as to serotonin 5-HT2 receptors. More binding to the latter and the early dissociation from D2 receptors explains the reduced incidence of EPS with SGAs. SGAs have metabolic side effects (weight gain, diabetes, and hyperlipidemia). In a case series of three DP patients started on risperidone 2mg/day increased upto 4--6mg, good improvement was seen within 3 months.\[[@ref11]\] In another study on DP, a good response was reported in three patients with olanzapine at a dose of 5mg/day increased to 10 mg.\[[@ref12]\] Aripiprazole, considered as a "third-generation antipsychotic," has also been tried in DP in the dose of 5--10 mg/day.\[[@ref13]\] One distinct advantage of aripiprazole over other SGAs is the absence of weight gain.\[[@ref14]\]

The principle of treatment is to start with a low dose and gradually titrate upward every 4 weeks depending on the response. During follow-up, all patients on antipsychotics should be questioned about EPS and also get their weight, blood sugars, lipid profile, and blood pressure checked. Elderly patients who are susceptible to side effects such as orthostatic hypertension and neuropsychiatric symptoms should be started with one-fourth to one-half the usual dose and slowly increased.\[[@ref15]\] The drug has to be continued till the improvement is maintained for a period of 3--6 months after which it can be tapered or stopped. If there is relapse, the drug can be restarted.

The oral dosing, side effects, and drug interactions of the commonly used anti psychotics are shown in [Table 1](#T1){ref-type="table"}.\[[@ref10]\] Adverse effects, monitoring schedule, management strategies of adverse effects of anti psychotics and strategies in selecting anti psychotics have been mentioned in [Table 2](#T2){ref-type="table"},\[[@ref16]\] [Table 3](#T3){ref-type="table"},\[[@ref16]\] [Table 4](#T4){ref-type="table"},\[[@ref16]\] and [Table 5](#T5){ref-type="table"}, respectively.

###### 

Pharmacological profile of antipsychotics

  Antipsychotic drug   Dosage       Side effects                             Drug interactions
  -------------------- ------------ ---------------------------------------- -----------------------------------------------------------
  Pimozide             1-8 mg/day   Sedation, EPS                            Azoles, macrolides, escitalopram, sertraline
  Risperidone          0.5-8 mg     Metabolic syndrome (MS), EPS, sedation   Carbamazepine, fluoxetine
  Aripiprazole         2-8 mg       MS, EPS, sedation                        Azoles, macrolides, fluoxetine, carbamazepine, rifampicin
  Olanzapine           2.5-7.5 mg   MS, sedation                             Carbamazepine, fluoxetine, fluvoxamine

###### 

Adverse effects of antipsychotics

  Adverse effects           Pim   Ola    Clo   Ari   Risp   Que    Zip    Lur
  ------------------------- ----- ------ ----- ----- ------ ------ ------ ------
  Anticholinergic effect    ++    ++     +++   0     0      +/++   0      0
  Acute Parkinsonism        ++    0/+    0     \+    ++     0      \+     +/++
  Akathisia                 +++   \+     \+    ++    \+     \+     +/++   +/++
  Tardive dyskinesia        \+    0/+    0     0/+   0/+    0/+    0/+    0/+
  Diabetes                  0     +++    +++   0/+   \+     ++     0/+    0/+
  Weight gain               0/+   +++    +++   0/+   ++     ++     0/+    0/+
  Increased lipids          0     +++    ++    0/+   \+     ++     0/+    0/+
  Sialorrhoea               0     0      ++    0     0      0      0      0
  Neutropenia               0     0/+    +++   0/+   0/+    0/+    0/+    0/+
  Orthostatic hypotension   0/+   ++     ++    0/+   \+     ++     0      0/+
  Hyperprolactinemia        ++    ++     \+    0     +++    0      \+     \+
  Increased QTc interval    +++   0/+    ++    0/+   \+     \+     ++     0/+
  Sedation                  \+    +/++   +++   0/+   \+     ++     \+     +/++
  Seizures                  0/+   0/+    ++    0/+   0/+    0/+    0/+    0/+

Ari=Aripiprazole, Clo=Clozapine, Lur=Lurasidone, Ola=Olanzapine, Que=Quetiapine, Ris=Risperidone, Zip=Ziprasidone, 0=None or equivocal, 0/+=Minimal/rare, +=Mild/sometimes occurs, ++=Moderate/occurs frequently, +++=Severe/occurs very often

###### 

Suggested monitoring schedule for antipsychotics

                            Baseline   During titration                           At 3 months   At 6 months   Annually
  ------------------------- ---------- ------------------------------------------ ------------- ------------- ----------
  Weight                    X          X                                                                      
  Tardive dyskinesia        X          X                                                        X             
  Akathisia, Parkinsonism   X          X                                                                      X
  FBS, HbA1C                X                                                     X                           X
  FLP                       X                                                     X                           X
  PR, BP                    X                                                     X                           X
  Sexual function           X          X                                                                      X
  Sedation                  X          X                                          X             X             X
  ECG (Based on symptoms)   X                                                                                 
  Prolactin                            If symptoms of hyperprolactinemia appear                               

BP=Blood Pressure, ECG=Electrocardiogram, FBS=Fasting Blood Sugar, FLP=Fasting Lipid Profile, PR=Pulse Rate

###### 

Management strategies of adverse effects of antipsychotics

  Adverse effects                                Option 1                    Option 2                                    Option 3
  ---------------------------------------------- --------------------------- ------------------------------------------- --------------------------------------
  Parkisnosim (tremor, rigidity, bradykinesia)   Dose reduction              Change antipsychotic                        Add anticholiergic agent
  Akathisia                                      Dose reduction              Change antipsychotic                        Use beta blocker
  Sedation                                       Dose at night               Lower the dose                              Change to non-sedating antipsychotic
  Hyperprolactinemia, sexual dysfunctions        Dose reduction              Change to prolactin sparing antipsychotic   Add aripiprazole
  Weight gain, dyslipidemia                      Lifestyle modification      Change antipsychotic                        Metformin
  Orthostatic hypotension                        Dose/scheduling titration   Adequate hydration                          Change antipsychotic
  QT prolongation                                Change antipsychotic                                                    

###### 

Clinical practice points for use of antipsychotics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In general, SGAs are preferred over FGAs.
  FGAs carry risk of EPS and SGAs can cause metabolic disturbance (clozapine and olanzapine have the highest risk).
  Newer SGAs may carry less of a risk of metabolic disturbances.
  Baseline and periodic monitoring of BMI, waist circumference, HbA1c, fasting plasma glucose, and fasting lipids for SGAs is recommended.
  If abnormalities are found in any of these parameters, following strategies can be tried: switching to an SGA that is less risky; titrating dose or discontinuing the agent; lifestyle modifications; seeking dietician and endocrinologist's opinion
  Monotherapy when appropriate to decrease the risk of side effects.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SGA=Second-generation antipsychotic, FGA=First-generation antipsychotic, EPS=Extra Pyramidal Syndrome, BMI=Body Mass Index, HbA1c=Glycated Hemoglobin

 {#sec2-1}

### Anti-anxiety agents {#sec3-1}

Anti-anxiety agents are chiefly used to mitigate anxiety symptoms seen as part of anxiety and/or other emotional disorders, most often in conjunction with antidepressant medications. Commonly encountered anxiety disorders include panic disorder, obsessive-compulsive disorder, specific phobias, social phobia, generalized anxiety disorder (GAD), and anxiety-related to other specific situations such as performance, health anxiety, etc. In a psychodermatology clinic, they are particularly useful in the management of social anxiety which more often than not accompanies chronic and disfiguring skin conditions.

### Benzodiazepines {#sec3-2}

These are the most commonly prescribed class of anxiolytic agents. They exert their anti-anxiety effect by binding to the benzodiazepine (BDZ) receptors at the gamma aminobutyric acid (GABA)-A ligand-gated chloride channel complex. This enhances the inhibitory effects of GABA and also increases chloride conductance through the GABA-regulated channels. These drugs presumably inhibit neuronal activity in amygdala- centered fear circuits to provide therapeutic benefits in anxiety disorders.

The classification of benzodiazepines and the doses of commonly used drugs are given in [Table 6](#T6){ref-type="table"}.

###### 

Classification and doses of various benzodiazepines

  Long-acting                              Intermediate-acting         Short-acting
  ---------------------------------------- --------------------------- --------------
  Chlordiazepoxide 15-40 mg in 3-4 doses   Alprazolam 1-4 mg/day       Midazolam
  Clorazepate                              Bromazepam                  Triazolam
  Diazepam 5-40 mg/day                     Clobazam                    
  Flurazepam                               Clonazepam 0.5-2.0 mg/day   
                                           Lorazepam 1-6 mg/day        
                                           Nitrazepam                  
                                           Oxazepam 15-120 mg          
                                           Temazepam                   

### Adverse effects {#sec3-3}

The most commonly reported side effect is that of sedation and day time drowsiness, which is partly dose-dependent. Patients also report weakness, giddiness, and impairment of motor performance such as driving, nausea, slight fall in blood pressure, confusion, and anterograde amnesia.\[[@ref17]\] Rarely, respiratory depression can occur, especially when taken with central nervous system (CNS) depressants in overdose. Most of these adverse effects usually wane over time. If they persist, dose may be reduced and the largest dose taken at bedtime to avoid day-time drowsiness. The chief concern with long-term use of BDZ is that it is habit-forming and patients may become dependent on the drug. Long-term use of BDZ may also cause tolerance leading to diminished efficacy at the same dose.\[[@ref18]\] Hence, short-term treatment is advocated, during which acute or self-limited episodes of anxiety often resolve.\[[@ref19]\]

Features of withdrawal include jitteriness, anxiety, palpitations, clamminess, sweating, nausea, confusion, and heightened sensitivity to sound and light. Seizures are the most worrisome withdrawal symptom, but they are fortunately rare. Patients may experience a rebound of the initial anxiety symptoms, in a more severe form than earlier, however, it is transient, usually lasting about 48--72 h. Hence, it has been advocated that these drugs should always be tapered gradually before discontinuation. One of the rules that have been suggested is to reduce the dose at a maximum rate of approximately 10% every day.

A study on BDZ withdrawal\[[@ref20]\] found that withdrawal symptoms on abrupt discontinuation were maximum in patients who had taken the medication for longer than 8 months. As a result of withdrawal, no patient had seizures in this study. Factors associated with a more difficult withdrawal included higher dose, use of a drug with a shorter half-life, longer duration of treatment, and more rapid taper.\[[@ref21]\] In the case of long-acting agents such as diazepam, withdrawal symptoms manifest only about 5--7 days after abrupt discontinuation, while they are more quickly evident in case of drugs like lorazepam.\[[@ref22]\]

Several medications have been tried in an attempt to alleviate the symptoms of benzodiazepine withdrawal and to make the transition as smooth as possible for the patient. Drugs such as buspirone have been found to be relatively safe, as also melatonin. The antidepressant trazodone relieves anxiety and depression and also promotes sleep while hydroxyzine is an alternative that can be easily procured over-the-counter. However, other medications such as carbamazepine, sodium valproate, lamotrigine, and phenobarbital that have high side-effect profiles and risks of medical complications must be used with caution. The evidence for the use of these drugs as a method of BDZ discontinuation remains poor. Flumazenil, which is used to reverse the effects of benzodiazepines, may precipitate seizures in patients with epilepsy being treated with benzodiazepines. The dosage of anxiolytics would generally need to be reduced in patients with renal, hepatic impairment, and in the pediatric and geriatric population. They are generally not recommended in pregnant and lactating women. A study comparing the efficacy and tolerability of clonazepam with other benzodiazepines in patients with anxiety disorders concluded that all benzodiazepines were equally efficacious in the treatment of anxiety disorders, however, clonazepam exhibited a better adverse effect profile than the other drugs.\[[@ref23]\]

### Buspirone {#sec3-4}

It is a 5-HT1A partial agonist, administered orally. The starting dose is 5 mg twice daily, increased upto 20--30 mg/day in divided doses. The major drawback of the drug is the delayed onset of action (2--4 weeks), which precludes its use on an as needed basis. It remains inappropriate for the treatment of acute situational stress because the therapeutic effect may not become evident until after the stressful event has been resolved.\[[@ref24]\] Side effects include dizziness, headache, nervousness, sedation, excitement, nausea, and restlessness. It has an advantage over benzodiazepines in that it is not habit-forming, hence does not require tapering before discontinuation. Side effects are time-limited. However, the dose may be reduced if they continue to be troublesome. Buspirone is primarily metabolized by CYP450 3A4, hence, dose needs to be adjusted when used along with inhibitors e.g., fluoxetine or inducers e.g., carbamazepine of the enzyme. A lower dose is also recommended in patients with hepatic and renal impairments and in the elderly. It is safer than benzodiazepines in pregnant and lactating women.

Anti-anxiety drugs are usually prescribed along with antidepressants, at the lowest effective dose. This dose is often continued for a period of 4--6 weeks until the anti-depressant drugs begin to act, following which it is gradually tapered and discontinued. Buspirone may be used for longer periods and does not require taper before discontinuation. The use of concomitant psychological interventions can also help in reducing the duration of treatment with anti-anxiety agents.

### Antidepressants {#sec3-5}

Depression can be an underlying, co-existing, or a consequence of the dermatological condition. When features of depression start manifesting and form part of or major component of the skin disease in course of dermatosis, antidepressants are indicated.

Diseases such as alopecia areata and vitiligo have been found to have a bidirectional relationship with depression in large scale cohort studies.\[[@ref25][@ref26]\] A systematic review of 35 studies found that chronic pruritus that is unresponsive to topical treatment and oral antihistamines will benefit from oral antidepressants (fluoxetine, fluvoxamine, paroxetine, sertraline, amitriptyline, nortriptyline, doxepin, and mirtazapine).\[[@ref27]\] Indications for antidepressants are outlined in [Table 7](#T7){ref-type="table"}.\[[@ref28][@ref29]\]

###### 

Indications of antidepressants

  ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  I. Primary psychiatric disorders related to skin                    1\. Dermatitis artefacta
                                                                      2\. Dermatitis para-artefacta: skin picking syndrome (neurotic excoriations), acne excoriee
                                                                      3\. Compulsive disorders: Eczema due to hand washing, Trichotillomania
                                                                      4\. Psychogenic pruritus
                                                                      5\. Somatoform disorders: somatoform pain disorders/cutaneous dysesthesias, itching, paresthesias, burning
  2\. Secondary psychiatric disorders due to dermatoses               Depression and anxiety secondary to chronic dermatosesEg: Atopic dermatitis, Prurigo, Psoriasis, Alopecia areata, Chronic urticarial
  3\. Treatment ofpsychiatric manifestations secondary to treatment   Isotretinoin: depression, suicidality
                                                                      Estrogen: depression, panic attacks
                                                                      Antiretrovirals: depression, suicidal thoughts
                                                                      Corticosteroids: depression, psychosis
                                                                      Dapsone: depression
                                                                      H2 antihistaminics: depression
                                                                      Acyclovir: depression (in high doses)
                                                                      Fluoroquinolones: depression
  ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------

### Classification {#sec3-6}

Antidepressants commonly used in a dermatologic setting are classified as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), tricyclic antidepressants (TCAs), and tetracyclic antidepressants (TeCAs). Others such as serotonin modulators and stimulators (SMSs), monoamine oxidase inhibitors (MAOIs), and norepinephrine reuptake inhibitors (NRIs) are rarely used. [Table 8](#T8){ref-type="table"} describes the dose, indications and side effects of antidepressants.\[[@ref30][@ref31][@ref32]\] [Table 9](#T9){ref-type="table"}[@ref33]\] mentions monitoring recommendations for antidepressants and [Table 10](#T10){ref-type="table"} describes about choosing the right antidepressant.

###### 

Antidepressants-pharmacological profile

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                     Recommended dose                                                                                 Psychiatry indication                                                                                                        Side effects
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Citalopram                                               20-60 mg/d at night\                                                                             Depression, OCD, Panic disorder, Social Phobia                                                                               Nausea, sleep disturbances, sexual dysfunctions, appetite changes, headache, dry mouth
                                                           Begin with 20mg/d Hike by 20 mg after 2-4 weeks in partial responders, maximum 60 mg/d                                                                                                                                        

  Escitalopram                                             10-30 mg/d at night\                                                                             Depression, Anxiety disorders, OCD                                                                                           
                                                           Start with 10mg/d and to increase by 5 mg after 2-4 weeks in partial responders, maximum 30m/d                                                                                                                                

  Fluoxetine                                               10-80 mg/d in morning\                                                                           Depression, Anxiety disorders, OCD, Premature ejaculation, Bulimia nervosa                                                   
                                                           Begin with 10mg/d and can be increased by 20mg after 4 weeks up to 80mg/d                                                                                                                                                     

  Fluvoxamine                                              100-300 mg/d at night or BD\                                                                     OCD, Depression, Post traumatic stress disorder                                                                              
                                                           Start with 50mg/d, and to increase by 50-100mg every 2-4 weeks up to 300 mg/day                                                                                                                                               

  Paroxetine                                               12.5-37.5 mg/d in morning\                                                                       Depression, Anxiety disorders, OCD, Premature ejaculation, Premenstrual dysphoric disorder                                   
                                                           Start with 12.5mg/d and to increase by 12.5 mg every 2 weeks up to 37.5 mg/d                                                                                                                                                  

  Sertraline                                               50-200 mg/d at night\                                                                            Depression, Anxiety disorders, OCD, Premenstrual dysphoric disorder                                                          
                                                           Start with 50 mg/d, hike by 50 mg/day every 2 weeks in partial responders, up to 200 mg/d                                                                                                                                     

                                                                                                                                                                                                                                                                                         

  **Serotonin Norepinephrine Reuptake Inhibitor (SNRI)**                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                         

  Venlafaxine                                              37.5-300mg at night or BD\                                                                       Depression, generalized anxiety disorder, panic disorder                                                                     Hypertension, tachycardia, nausea, sleep disturbances, sexual dysfunctions, appetite changes, headache, dry mouth
                                                           Start with 37.5 mg/d and to increase by 37.5 mg/d every 2-4 weeks up to 300 mg/d                                                                                                                                              

  Desvenlafaxine                                           50-100 mg/d at night\                                                                            Depression                                                                                                                   
                                                           Start with 50mg/d and increase by 50 mg after 4 weeks in partial responders                                                                                                                                                   

  Duloxetine                                               20-60 mg/d twice daily\                                                                          Depression, generalized anxiety disorder, diabetic neuropathy, fibromyalgia, chronic pain                                    
                                                           Start with 20mg/d and increase by 20mg every 2 weeks                                                                                                                                                                          

                                                                                                                                                                                                                                                                                         

  **Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)**                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                         

  Bupropion                                                150-450 mg/d in morning\                                                                         Depression, smoking cessation                                                                                                Seizures, headache, insomnia
                                                           Start with 150mg/d and increase by 150 mg/d after 4 weeks in partial responders                                                                                                                                               

                                                                                                                                                                                                                                                                                         

  **Tricyclic Antidepressant (TCA)**                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                         

  Amitriptyline                                            25-150 mg/d at night\                                                                            Depression, migraine, neuropathic pain, fibromyalgia                                                                         Dry mouth, dizziness, blurred vision, constipation, sedation, orthostatic hypotension, tachycardia
                                                           Start with 25 mgd and to increase by 25 mg every 2 weeks                                                                                                                                                                      

  Clomipramine                                             25-250 mg/d at night                                                                             OCD, depression, panic disorder, body dysmorphic disorder, Trichotillomania, enuresis, chronic pain, premature ejaculation   

  Doxepin                                                  25-150 mg/d at night                                                                             Depression, anxiety disorder, chronic hives                                                                                  

  Imipramine                                               25-150 mg/d                                                                                      Depression, nocturnal enuresis                                                                                               

                                                                                                                                                                                                                                                                                         

  **Tetracyclic Antidepressant (TeCA)**                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                         

  Mirtazapine                                              7.5-30 mg/d at night\                                                                            Depression                                                                                                                   Drowsiness, increased appetite, weight gain, hypercholesterolemia, cardiac disturbance
                                                           Start with 7.5 mg/d and increase by 7.5mg every 2 weeks                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OCD=Obsessive compulsive disorder

###### 

Monitoring recommendations for antidepressants

  Monitoring parameter            Agent                                     Frequency                                                                                         Remarks
  ------------------------------- ----------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  ECG for QT prolongation         TCAs                                      Baseline, After initial dose titration and at dose changes                                        More caution is indicated in children, elderly, and at higher doses
  Liver function test             Agents with hepatic liability             Baseline and at 6, 12, and 24 months and when indicated                                           Specially in people with liver dysfunctions
  BMI, Waist circumference        Agents with known weight gain liability   Baseline and 6 monthly                                                                            More caution with Mirtazapie, TCAs
  Electrolytes for hyponatremia   SSRIs, SNRIs, TCAs, Mirtazapine           Baseline and after 1 month if indicated in high-risk groups, especially in \>65 years age group   More frequent monitoring in renal impairment or existing hyponatremia patients
  Blood Pressure monitoring       Venlafaxine, TCAs                         Baseline, during titration and 3 monthly                                                          Closer monitoring in initial periods
  Sexual functioning              SSRIs                                     Baseline, 3 monthly                                                                               Decreased libido, premature/delayed ejaculation

BMI=Body Mass Index, ECG=Electrocardiogram, SNRI=Serotonin norepinephrine reuptake inhibitor, SSRI=Selective serotonin reuptake inhibitor, TCA=Tricyclic antidepressant

###### 

Choosing an antidepressant

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clear indication definition: Unequivocal diagnosis of the primary disorder andsecondary symptoms
  Determination of target symptoms
  Desired effect: Selection of the substance depending on its mode of action
  Consideration of undesired side effects
  Clear performance and long-term control strategy (advance information about side effects, delayed onset of action, and dose titration)
  Some unique points of antidepressant treatment to consider
   Same antidepressant may act differently in different patients
   Antidepressant from the same group may act differently in the same patient
   Antidepressant dose differs from patient to patient
   Selection and indications of antidepressant may be made on basis of the side effects profile
   The off-label use of antidepressants in dermatology is sometimes due to a lack of studies
   A foresighted treatment plan and patient motivation are necessary to an extent, especially because the onset of effect is often evident only after couple of weeks
   Antidepressant initial therapy is administered for 2-3 weeks before an optimal therapeutic dose range is found. Maximal-dose therapy should be administered for 6 weeks before efficacy is rated (or the substance changed)
   The duration of therapy for the first appearance of disease is 6-9 months on average
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Selective serotonin reuptake inhibitors {#sec3-7}

These increase levels of serotonin in the synaptic cleft by inhibiting its reuptake into presynaptic cells. They are preferred as first-line antidepressants due to their better tolerability and favorable side effects profile.

A study to determine if psoriasis was affected by the use of SSRIs showed that the risk of switching from non-systemic to systemic psoriasis treatments was significantly decreased in the SSRI-exposed group.\[[@ref34]\] In a retrospective study of 51 patients suffering from primary burning mouth syndrome, SSRIs appeared to be effective and well-tolerated.\[[@ref35]\]

Citalopram/Escitalopram

Escitalopram is an S-stereoisomer of its predecessor citalopram and has the highest affinity for serotonin receptors among all SSRIs and more cost-effective.\[[@ref36]\]

In a double-blind RCT of citalopram (20 mg/day, over 4 weeks) in 45 patients with pathological skin picking, there was a significant improvement with citalopram compared to placebo.\[[@ref37]\] In an open-label trial of escitalopram for 18 weeks in 29 patients with pathological skin picking, 44.8% showed full remission and 27.6% showed partial response.\[[@ref38]\]

Fluoxetine

It is useful in neurotic excoriations, pathologic skin picking, and body dysmorphic disorder.\[[@ref39][@ref40]\] In an open-label double-blind study to check the usefulness of fluoxetine in pathological skin picking, of 15 recruited eight responded by 6 weeks. On randomization, four patients on fluoxetine maintained improvement, the other four patients on placebo, returned to baseline symptom level.\[[@ref39]\]

Fluvoxamine

Its antidepressant property is enhanced by its affinity (maximum among SSRIs) for the σ1 receptor.\[[@ref41]\] It is useful in patients with neurotic excoriations, chronic pruritus, body dysmorphic disorder and trichotillomania (TTM).

In a 12 weeks uncontrolled study of flexible-dose of fluvoxamine (25--50 mg/day - 300 mg/day) over 12 weeks in skin picking, all 14 patients showed significant reduction in behaviors involving the skin (e.g., scratching, picking, gouging, or squeezing), increased control over skin behavior and a significant improvement in the presence of skin sensations, skin appearance, and lesions.\[[@ref42]\]

Paroxetine

It has been used successfully in patients with TTM and pathologic picking.\[[@ref43]\] In a case series of eight adolescents with acne and depression, paroxetine was beneficial in improving both depression and acne.\[[@ref44]\] In a double-blind, randomized, placebo-controlled trial with paroxetine in 13 patients (eight-paroxetine and five placebo) with alopecia aerate and psychiatric comorbidity, complete regrowth of hair was seen in two patients on paroxetine, while four showed partial regrowth. Only one in placebo group had an almost complete hair regrowth.\[[@ref45]\] It can cause weight gain, memory impairment, paresthesias and reproductive risks, as it may cause sperm DNA fragmentation.\[[@ref46]\]

Sertraline

It can be used in the treatment of neurotic excoriations and chronic pruritus.\[[@ref27]\] With a response rate of 68% in an open-label trial using flexible-dose of sertraline, it also emerged as a promising agent for reducing skin-picking.\[[@ref47]\]

Discontinuation syndrome\[[@ref48]\] if SSRIs are abruptly stopped, patients may experience nausea, weakness, dizziness, insomnia, anxiety, irritability and headache. It is seen with paroxetine and fluvoxamine which have short half-lives and less with fluoxetine, which has a longer half-life. Usually, the symptoms tend to resolve within a week and can be prevented by slowly tapering SSRIs over a few weeks.

### Serotonin Norepinephrine Reuptake Inhibitors {#sec3-8}

This group includes drugs that inhibit serotonin and norepinephrine reuptake.

Venlafaxine

It is considered to be superior to SSRIs and TCAs.\[[@ref49]\] It may be particularly useful in patients who have mixed symptoms of depression and anxiety because it has anxiolytic properties.

Duloxetine: Although useful in depression, diabetic neuropathy and somatoform disorders, it has been successfully tried in burning mouth syndrome.\[[@ref50]\]

### Norepinephrine dopamine reuptake inhibitor {#sec3-9}

Bupropion is a NDRI and a nicotinic and acetylcholine receptor antagonist. It does not cause sexual dysfunction. It can lower the seizure threshold and can unmask underlying psychosis.\[[@ref51]\] Ten patients with psoriasis and ten patients of atopic dermatitis, without depression were studied in a single track open-label treatment with bupropion -- sustained release (SR) with 150 mg/day and 300 mg/day doses, given sequentially for 3 weeks with a washout period of 3 weeks. In atopic dermatitis group, six of ten subjects showed a reduction in affected body surface area by the end of 6 weeks of bupropion treatment, with affected area increasing toward the pre-study baseline in all responders following bupropion discontinuation. Eight of ten patients improved after 6 weeks of treatment in psoriasis group. Average reduction in the affected area in the responders at week 6 of treatment was approximately 50% in both groups.\[[@ref52]\]

### Tricyclic and tetracyclic antidepressants {#sec3-10}

Both groups of drugs inhibit serotonin and norepinephrine reuptake, in addition they block histamine, muscarinic acetylcholine, and noradrenergic receptors, which account for their antidepressant effects and adverse effects. When imipramine was compared with placebo in a double-blind study of 13 patients for 6 months, five of seven patients receiving imipramine showed significant regrowth of hair, whereas no change was noticed in placebo group.\[[@ref53]\]

Doxepin

This is the most relevant and commonly used TCA in dermatology because of its H1 and H2 histamine-blocking activity. It can be considered as first-line "off-label" treatment for neurotic excoriations, generalized pruritus, and chronic urticaria.\[[@ref54]\] It is available in the topical cream formulation also for pruritus. In a retrospective, cross-sectional study over a 20-year period (1998-2017) of 36 patients with chronic urticaria who had poor antihistamine responses and received doxepin therapy, 16 (44.4%) patients showed a complete response and it was effective in 27 (75%) patients with a short onset time.\[[@ref55]\] In a double-blind cross-over study of 50 patients with chronic idiopathic urticaria, doxepin (10 mg TDS) with diphenhydramine (25 mg TDS), 43% of the patients on doxepin had a complete response (total clearance of pruritus and urticarial lesions), whereas only 5% of patients receiving diphenhydramine had responded; partial or total control of urticaria and itch was found in 74% of patients receiving doxepin and only in 10% of patients on diphenhydramine.\[[@ref56]\]

In a case series of 11 patients with scalp dysesthesia, nine benefitted with antidepressants, eight patients experienced improvement/complete resolution with low-dose doxepin or amitriptyline and one patient completely responded to sertraline and hydroxyzine hydrochloride but then experienced a relapse.\[[@ref57]\]

Mirtazapine

It is a tertracyclic antidepressant (TeCA) as well as noradrenergic and specific serotonergic antidepressant that antagonizes adrenergic α2-auto- and α2-heteroreceptors as well as 5-HT2 and 5-HT3 receptors.\[[@ref58]\] It is useful for pruritus in patients with malignancy, cholestasis, renal failure, atopic dermatitis, and neurotic excoriations.

In a case series of four cases mirtazapine was found effective for pruritus associated with advanced cancer, cholestasis, and hepatic and renal failure.\[[@ref59]\] In an open, uncontrolled pilot study of three non-depressed patients with inflammatory skin diseases and severe nocturnal pruritus, after treatment with mirtazapine, all showed improvement in itching.\[[@ref60]\]

Antidepressant medications such as paroxetine (20--50 mg/day), sertraline (25--200 mg/day), fluoxetine (10--60 mg/day), escitalopram (10--20 mg/day), low-dose doxepin (50 mg/day or less), and venlafaxine extended-release (75--150 mg/day) have also been shown to be useful for the treatment of chronic anxiety.\[[@ref24]\] Occasionally, use of SSRI\'s may be associated with a worsening of anxiety symptoms in the initial days of treatment.\[[@ref61]\] Ameta-analytic review of studies that compared the use of benzodiazepines and serotonergic antidepressants in patients with generalized anxiety disorder (GAD) concluded that benzodiazepines are a viable treatment option for adults with GAD, particularly in the initial treatment phases. The review, however, did not minimize the role of antidepressant agents as treatment for the same and suggested that the combined use of the two could yield optimum risk-benefit ratio of both the medications.\[[@ref62]\]

Cutaneous side effects associated with antidepressants include pruritus, exanthematous rash, urticarial, angioedema, fixed drug reactions, photosensitive reactions, pigmentation, alopecia, psoriasiform reactions, acneiform reaction, seborrheic dermatitis, and hyperhidrosis. Serious reactions such as erythema multi for me, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), vasculitis, erythroderma, and erythema nodosum have also been reported.\[[@ref63]\]

Choosing the right antidepressant: The choice depends on side-effect profile, drug interactions, and comorbid conditions. First-line drugs are generally SSRIs such as escitalopram or sertraline. In those with disturbed sleep, mirtazapine or TCAs are preferred. In overweight patients, bupropion may be tried. It also aids in smoking cessation. SSRIs are safe in pregnancy and lactation. Dose varies from patient to patient. The initial dose is given for atleast 2--3 weeks. The maximum tolerated dose should be given for at--least 6 weeks for assessing efficacy. Treatment should be continued for a minimum of 6 -- 9 months.\[[@ref64]\]

Selecting antidepressant for pruritus

Selection of antidepressant for pruritus, which is unresponsive to conventional treatment, depends on cause of pruritus, age, and medical comorbidities. In review, paroxetine (20 to 30 mg/d) and mirtazapine (10 to 20 mg/d) have emerged as effective therapeutic options for pruritus due to malignancies. Sertraline (50--150 mg/d) is an effective therapeutic option for pruritus due to chronic kidney disease or cholestasis. Amitriptyline (10 to 25 mg/d) and doxepin (10 to 20 mg/d) have also been useful in uremic pruritus. For unexplained pruritus, not responding to conventional treatment, most evidence is available for paroxetine. Dose titrations have been mentioned in the [Table 8](#T8){ref-type="table"}.

### Miscellaneous agents {#sec3-11}

Anticonvulsants

PD indications of anti-epileptics include cutaneous neuropathic pain, itch, and complex cutaneous sensory syndromes, where CNS sensitization plays a role, repetitive excoriation behaviors such asprurigo nodularis, lichen simplex chronicus, skin picking, and TTM, psychophysiologic conditions such as urticaria, flushing, and social anxiety.\[[@ref65]\]

Carbamazepine has been tried in neuropathic and chronic pain,\[[@ref24]\] lamotrigine in pathologic skin picking,\[[@ref66]\] and topiramate\[[@ref67]\] in neurogenic pruritus, and skin picking. However, all these are not extensively used.

Present review focuses on commonly used drugs i.e., the Gamma aminobutyric acid (GABA) elevators.

### Gamma aminobutyric acid elevators or neuroleptics {#sec3-12}

These are used for relief of neuropathic pain syndromes,\[[@ref68]\] peripheral neuropathic and psychogenic itch, brachioradial pruritus, various allodynias, collectively known as cutaneous dysaesthesias. These include gabapentin and pregabalin, which inhibit neuropathic afferent pathway.

Gabapentin is a structural analogue of the neurotransmitter GABA. The starting dose is 300 mg at bedtime, increased by 300 mg every 2 to 3 days upto a maximum of 2400 mg/day. It has a lower potential for abuse. Side effects include somnolence, fatigue, ataxia, dizziness, gastrointestinal upset, dyspnea, peripheral edema, and weight gain.

A study involving 17 women with vulvodynia reported 82% response rate to gabapentin\[[@ref69]\] a case series of 4 patients with glossodynia responded well to gabapentin\[[@ref70]\] and another study on recalcitrant prurigo nodularis also reports good efficacy.\[[@ref71]\]

Gabapentin has an off-label use for anxiety disorders. The onset of action is less rapid than benzodiazepines but faster than buspirone. The potential for abuse is lower, and it confers an added advantage of anti-pruritic effect.

Pregabalin is used at a dose of 150 mg per day, to a maximum of 600 mg per day. For neuropathic pruritus, starting dose is 75 mg bd, then slowly increased upto 300 mg per day. Side effects include dryness of mucosae, constipation, nausea, vomiting, flatulence, drowsiness, memory impairment, and rarely, serious cutaneous adverse reactions like SJS. Peripheral edema is encountered in 4--16% cases and weight gain in 4--12%.

Withdrawal of neuroleptics should be gradual, over a period of time, and should be used with caution in congestive cardiac failure (CCF) and renal impairment. Dosage adjustment is not required in hepatic disease and depends on the creatinine clearance rate in renal disease.

### Naltrexone {#sec3-13}

This is an opioid antagonist chiefly used in the treatment of alcohol use disorder and opioid abuse but has an off-label indication for treating cholestatic pruritus and psychogenic pruritus as well as intractable pruritus contributing to psychological stress in inflammatory disorder.\[[@ref72]\] A systematic review evaluating 22 RCTs, case series, and reports for the utility of naltrexone in dermatology found it to be effective in intractable pruritus associated with inflammatory diseases.\[[@ref73]\] Low dose naltrexone (1.5--4.5 mg/day) was more effective as an anti-inflammatory agent in dermatology than high dose naltrexone (12.5--50 mg/day).\[[@ref73]\] A meta-analysis of RCTs on naltrexone in the treatment of broadly defined behavioral addictions, which included TTM and skin picking showed a beneficial effect.\[[@ref74]\] Dose adjustment is warranted in moderate to severe renal failure, and it is contraindicated in severe hepatic failure. Adverse effects include syncope, dizziness, headache, insomnia, nausea, vomiting, abdominal pain, anorexia, arthralgia, myalgia, pharyngitis, and increased levels of AST, ALT, CPK, and GGT.

### N-acetyl cysteine {#sec3-14}

This thiol amino acid, a donor of cysteine, restores extracellular glutamate within the nucleus accumbens, the area of the brain associated with reward and motivation. It also alters dopamine level in neurons and has additional anti-inflammatory, potent antioxidant, vasodilator, and antiproliferative effects on fibroblasts and keratinocytes.\[[@ref75]\]

Indications include TTM, trichoteiromania, onychotillomania, onychophagia, skin picking, and neurotic excoriations.\[[@ref76]\] Usual dose is 1200 mg per day, given as 600 mg bd, increased upto a maximum of 3000 mg per day. Cochrane\'s systemic review demonstrates good evidence for its usefulness in TTM. There are studies substantiating\[[@ref77]\] as well as refuting its effectiveness in TTM.\[[@ref78]\]

At1, 200--2,400 mg per day, N-acetyl cysteine (NAC) significantly improved TTM showing a 56% improvement in TTM scale, as compared with placebo.\[[@ref77]\] An RCT in skin picking (excoriation disorder) found it to be effective with very good improvement in 47% cases.\[[@ref76]\] In onychophagia, an RCT showed statistically significant short-term improvement on 800 mg NAC per day, though many relapsed.\[[@ref79]\] Side effects include disagreeable taste, nausea, vomiting, abdominal pain, constipation, urticaria, skin rash, fever, and headache. It is contra-indicated in patients on nitroglycerine as it can cause vasodilatory hypotension and reverse the tolerance to nitroglycerates.\[[@ref75]\]

### Lactium {#sec3-15}

This is a milk protein hydrosylate, which contains a bioactive decapeptide, α-casozepine. It is a non-sedative, non-addictive anxiolytic which is claimed to be helpful in disease-associated anxiety by potentiating the effect of GABA by binding to GABA-A receptors causing an influx of chloride ions which hyperpolarizes the neurons and decreases the transmission of stress signals.\[[@ref80]\] In spite claims, there are no studies regarding its efficacy.

### Special populations {#sec3-16}

Children, adolescents, geriatric age group patients and patients with medical comorbidities constitute this group. General dictum for the usage of psychotropics in the geriatric population is "start low, go slow". For children and adolescents, lowest possible doses are suggested. The selection of psychotropic will depend on a person\'s medical comorbidity.

Conclusions {#sec1-3}
===========

Patients with the suspected psychodermatologic disease should be assessed with a thorough psychiatric history. The appropriate psychotropics may be started according to the psychiatric diagnosis. It is better to be familiar with one or two drugs from each class. Usual doses required for treatment in dermatological conditions are much lesser than what are used in psychiatry. Adverse effects encountered with psychotropics are usually at higher doses, which are used for major psychiatric disorders, and at doses used in dermatology, chances of encountering adverse effects are minimal. However, the selection of a psychotropic depends on condition and comorbidities of patient and personalized therapy is the need of 3 h rather than one drug for one condition for all. Starting with a low dose and gradual escalation, being watchful for side effects and tapering before discontinuation is the key to effective management.
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